Medication info
Maxebika Tablet 10/40 Milligrams

Maxebika Tablet 10/40 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
McNulty Pharmaceutical Co., Ltd.
Appearance
Brownish-red round film-coated tablet
Packaging
30 tablets - 10 tablets/Alu-Alu[*3]
Approval status
Active

MFDS item code 201902308 · Approved 2019.04.15 · Insurance code 641502410

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum antihypertensive effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose with close monitoring of their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this medicine to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
Pediatric patients under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
McNulty Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential Hypertension
View approved original text

This medication is used to treat essential hypertension that is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil. It effectively lowers blood pressure and helps prevent cardiovascular complications.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum antihypertensive effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose with close monitoring of their condition. ∘Patients with hepatic impairment: Use caution when administering to patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. Do not administer this medicine to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

Pediatric patients under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Do not take this medication if you have allergies to any of its ingredients, are pregnant or breastfeeding, or have severe liver disease or aortic stenosis. Caution is required for patients with low body water or sodium, as initial dosage may result in excessively low blood pressure, necessitating appropriate management if blood pressure drops too low. Due to the vasodilatory effect, this medication should be used cautiously in patients with aortic stenosis, severe obstructive coronary artery disease, or heart failure. Patients with compromised kidney function may need regular kidney function tests, as this medication could affect renal function. Patients with severe liver impairment should also use this medication with caution, as it may remain in the liver for an extended period. While taking this medication, side effects such as dizziness, headaches, blood pressure drops, swelling, and dyspepsia may occur, and any unusual symptoms should be discussed with healthcare professionals. This medication may interact with other antihypertensive drugs or specific medications, so it is essential to inform your healthcare provider about any other medications you are taking. Particularly, concurrent use with grapefruit juice can lead to excessive blood pressure-lowering effects, hence should be avoided. If you are pregnant or planning to become pregnant, it is recommended to switch to another antihypertensive medication with proven safety instead of using this one. Breastfeeding women should discontinue breastfeeding or stop taking this medication, as it may be passed to breast milk and affect the baby. Children under 18 years of age should not use this medication as its safety and efficacy have not been established. Elderly patients should start with lower doses, considering diminished kidney and liver function, and be monitored for potentially sensitive reactions. In cases of overdose, blood pressure may drop sharply, so seek immediate medical attention if symptoms occur. This medication should be stored away from moisture, heat, and light in a place out of reach of children, and transferring it to another container should be avoided.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • diminished perception
  • syncope
Show 89 more
  • vertigo
  • palpitations
  • rapid heartbeat
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • indigestion
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute kidney failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • rhabdomyolysis
  • hair loss
  • itching
  • urticaria
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema
  • bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best to maintain storage temperatures between 1 to 30 degrees Celsius at room temperature to preserve its effects for a longer duration.

Appearance and packaging

Appearance

Brownish-red round film-coated tablet

Package unit

30 tablets - 10 tablets/Alu-Alu[*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.